I. Cov ntaub ntawv dav dav

Tsis ntev los no, Tianjin Lisheng Pharmaceutical Co., Ltd. (tom qab no hu ua "Lub Tuam Txhab") tau txais Daim Ntawv Ceeb Toom Kev Pom Zoo rau Kev Lag Luam Kev Siv Tshuaj Siv Tshuaj Siv Tshuaj rau Febuxostat API (pom zoo No.: 2023YS00313) tawm los ntawm National Medical Products Administration (NMPA). Cov khoom lag luam tau dhau daim ntawv thov kev lag luam rau cov tshuaj active tshuaj cov khoom xyaw.

II. Cov ntaub ntawv tseem ceeb ntawm cov khoom

Lub Npe Lub Npe: Febuxostat

Lub npe Askiv: Febuxostat

Lub npe tshuaj: 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

Molecular Luj: 316.37

Molecular Formula: C₁₆H₁₆N₂O₃S

CAS Nr .: 144060-53-7

Chaw tsim tshuaj paus: Tianjin Lisheng Pharmaceutical Co., Ltd.

Daim Ntawv Thov Cov Ntsiab Lus: Daim ntawv thov kev lag luam rau cov khoom siv tshuaj active tshuaj

Txais No.: CYHS2160527

Daim Ntawv Pom Zoo Pom Zoo: Pom zoo rau kev lag luam raws li cov khoom siv tshuaj active tshuaj

III. Cov ntaub ntawv ntsig txog cov khoom

Febuxostat yog 2-arylthiazole derivative thiab xanthine oxidase (XO) inhibitor. Nws txo cov ntshav uric acid concentration los ntawm inhibiting uric acid synthesis thiab txhawb uric acid excretion.Nws yog qhia rau kev kho mob ntev ntawm hyperuricemia hauv cov neeg mob gout. Nws tsis pom zoo rau asymptomatic hyperuricemia.As cov pa tshuaj ntau ntau, nws tsis cuam tshuam lwm cov enzymes koom nrog hauv purine thiab pyrimidine synthesis thiab metabolism. Cov kev tshawb fawb soj ntsuam tau pom tias cov ntsiav tshuaj febuxostat muaj kev nyab xeeb thiab siv tau zoo hauv kev kho mob ntawm cov neeg mob gout thiab hyperuricemia.